- Lilly and Incyte reported that the US FDA has extended the review period of sNDA for baricitinib to treat adults with mod. to sev. atopic AD
- The FDA has extended the action date, allowing the time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA. The PDUFA date has been extended 3 mos. to early Q3’21
- The companies are evaluating baricitinib in adult and pediatric patients with AD, AA, SLE, JIA, COVID-19 and also continues for RA
Click here to read full press release/ article | Ref: PRNewswire | Image: The Straits Times
The post The US FDA Extends Review Period of Olumiant’s sNDA to Treat Moderate to Severe Atopic Dermatitis first appeared on PharmaShots.